Septerna, Inc. (NASDAQ:SEPN) Receives $43.13 Average Price Target from Brokerages

Septerna, Inc. (NASDAQ:SEPN) has been given a consensus recommendation of “Moderate Buy” by the eleven brokerages that are covering the company, Marketbeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, one has assigned a hold recommendation, seven have assigned a buy recommendation and two have issued a strong buy recommendation on the company. The average 12-month target price among analysts that have covered the stock in the last year is $45.7778.

SEPN has been the topic of a number of recent analyst reports. Wall Street Zen downgraded shares of Septerna from a “buy” rating to a “hold” rating in a report on Saturday, March 14th. Truist Financial increased their price target on shares of Septerna from $34.00 to $35.00 and gave the stock a “buy” rating in a report on Wednesday, March 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Septerna in a report on Tuesday, April 21st. Raymond James Financial increased their price target on shares of Septerna from $47.00 to $53.00 and gave the stock a “strong-buy” rating in a report on Monday, June 8th. Finally, JPMorgan Chase & Co. increased their price target on shares of Septerna from $34.00 to $38.00 and gave the stock an “overweight” rating in a report on Tuesday, March 24th.

Septerna Price Performance

NASDAQ SEPN opened at $35.95 on Monday. The company has a market cap of $1.62 billion, a PE ratio of -44.38 and a beta of 2.39. Septerna has a 52 week low of $9.85 and a 52 week high of $36.26. The firm’s 50-day simple moving average is $26.98 and its two-hundred day simple moving average is $26.78.

Septerna (NASDAQ:SEPN) last released its quarterly earnings data on Tuesday, May 12th. The company reported ($0.19) EPS for the quarter, beating the consensus estimate of ($0.42) by $0.23. The business had revenue of $26.52 million for the quarter, compared to the consensus estimate of $16.98 million. Septerna had a negative net margin of 49.88% and a negative return on equity of 12.72%. As a group, equities research analysts anticipate that Septerna will post -1.57 EPS for the current year.

Insider Transactions at Septerna

In other news, insider Samira Shaikhly sold 5,935 shares of the stock in a transaction dated Monday, June 1st. The shares were sold at an average price of $28.93, for a total value of $171,699.55. Following the sale, the insider directly owned 793 shares of the company’s stock, valued at approximately $22,941.49. This represents a 88.21% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Also, COO Elizabeth Bhatt sold 4,000 shares of the stock in a transaction dated Wednesday, April 15th. The stock was sold at an average price of $24.34, for a total transaction of $97,360.00. Following the completion of the sale, the chief operating officer directly owned 174,209 shares in the company, valued at approximately $4,240,247.06. The trade was a 2.24% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 21,733 shares of company stock worth $623,707. Insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of the stock. Janus Henderson Group PLC bought a new position in shares of Septerna in the first quarter worth approximately $21,334,000. First Light Asset Management LLC increased its position in shares of Septerna by 18.0% in the first quarter. First Light Asset Management LLC now owns 732,860 shares of the company’s stock worth $17,611,000 after purchasing an additional 112,049 shares during the last quarter. Renaissance Technologies LLC bought a new position in shares of Septerna in the first quarter worth approximately $906,000. Swiss National Bank bought a new position in shares of Septerna in the first quarter worth approximately $531,000. Finally, Bank of New York Mellon Corp increased its position in shares of Septerna by 6.1% in the first quarter. Bank of New York Mellon Corp now owns 58,709 shares of the company’s stock worth $1,411,000 after purchasing an additional 3,377 shares during the last quarter.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases. GPCRs are the largest and most diverse family of cell membrane receptors and regulate physiological processes in nearly every organ system of the human body.